Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Xspray Pharma in connection with a directed share issue (1)
Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

December 10, 2018 Capital Markets and Public M&A

The board of directors of Xspray Pharma AB (publ) has resolved on a directed new issue of shares, whereby Xspray Pharma will raise proceeds of approximately SEK 92 million, before issue costs. 

Xspray Pharma is a product development company with several product candidates in clinical development. Xspray Pharma uses its patented RightSize technology to develop improved generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Edin Agic and Julia Hirschberg.

Related

Vinge advises Advania on the acquisition of Cortex Consult A/S

 Vinge has advised Advania on the acquisition of Cortex Consult A/S, a Danish IT services company with more than 25 years of experience in managed IT services, cloud solutions and cybersecurity for customers across a range of industries.
August 18, 2026

Vinge advises Radonova Laboratories on the acquisition of the Norwegian company Skandinavisk Radoninvest

 Radonova Laboratories, a subsidiary of the Lagercrantz Group, has acquired all the shares in the Norwegian company Skandinavisk Radoninvest. Both companies operate in the field of radon measurement.
August 14, 2026

Vinge has advised KLAR Partners in connection with its divestment of Swoosh Group to Serwent

 Swoosh is a leading provider of inspection, maintenance, and services for underground infrastructure in Sweden, delivering sewer pipe inspection, cleaning, repair, and maintenance to municipalities, industrial operators, and property owners across 23 sites nationwide. Swoosh today employs approximately 450 people and generates revenues of nearly SEK 700 million.
August 13, 2026